DK0588917T3 - Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion - Google Patents
Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktionInfo
- Publication number
- DK0588917T3 DK0588917T3 DK92912971T DK92912971T DK0588917T3 DK 0588917 T3 DK0588917 T3 DK 0588917T3 DK 92912971 T DK92912971 T DK 92912971T DK 92912971 T DK92912971 T DK 92912971T DK 0588917 T3 DK0588917 T3 DK 0588917T3
- Authority
- DK
- Denmark
- Prior art keywords
- isoxazole
- cognitive function
- enhance cognitive
- treatment
- isothiazole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70692091A | 1991-05-29 | 1991-05-29 | |
PCT/US1992/004631 WO1992021339A1 (en) | 1991-05-29 | 1992-05-28 | Isoxazole and isothiazole compounds that enhance cognitive function |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0588917T3 true DK0588917T3 (da) | 2001-02-12 |
Family
ID=24839628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92912971T DK0588917T3 (da) | 1991-05-29 | 1992-05-28 | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion |
Country Status (13)
Country | Link |
---|---|
US (1) | US5409946A (pt) |
EP (1) | EP0588917B1 (pt) |
JP (1) | JP3153551B2 (pt) |
AT (1) | ATE197454T1 (pt) |
BR (1) | BR1100981A (pt) |
CA (1) | CA2109585C (pt) |
DE (1) | DE69231557T2 (pt) |
DK (1) | DK0588917T3 (pt) |
ES (1) | ES2153360T3 (pt) |
GR (1) | GR3035285T3 (pt) |
IE (1) | IE921690A1 (pt) |
PT (1) | PT100525B (pt) |
WO (1) | WO1992021339A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0665833B1 (en) * | 1992-10-23 | 1999-07-14 | MERCK SHARP & DOHME LTD. | Dopamine receptor subtype ligands |
US5424444A (en) * | 1992-11-25 | 1995-06-13 | Abbott Laboratories | Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles |
US5494680A (en) * | 1993-12-08 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Transdermal delivery device |
US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
DE19501022C1 (de) * | 1995-01-14 | 1996-06-05 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung |
AU5014396A (en) * | 1995-03-24 | 1996-10-16 | Japan Tobacco Inc. | Diazabicyclo{3.3.1}nonane derivatives and intermediates ther eof, medicinal use of the same, and processes for producing the same |
US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
US5723414A (en) * | 1996-01-24 | 1998-03-03 | Rohm And Haas Company | 5-aryl-isoxazolinones and herbicidal use thereof |
EP0900200B9 (en) | 1996-04-23 | 2009-10-21 | Targacept, Inc. | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5706829A (en) * | 1996-06-06 | 1998-01-13 | Creighton University | Method for treating neurocardiogenic syncope |
US6166032A (en) * | 1997-02-07 | 2000-12-26 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
IL132437A0 (en) | 1997-05-30 | 2001-03-19 | Neurosearch As | 8-Azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors |
CN1205210C (zh) * | 1997-05-30 | 2005-06-08 | 神经研究公司 | 作为尼古丁ACh受体上胆碱能配体的9-氮杂双环(3.3.1)壬-2-烯衍生物 |
AU736547B2 (en) | 1997-05-30 | 2001-08-02 | Neurosearch A/S | Azacyclooctane and heptane derivatives, their preparation and use in therapy |
US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
US6133002A (en) * | 1997-09-25 | 2000-10-17 | Dsm N.V. | Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
EP1274444B1 (en) * | 2000-03-16 | 2013-05-15 | THE McLEAN HOSPITAL CORPORATION | Cdp-choline and uridine for the treatment of alcohol abuse |
AU2003291368A1 (en) * | 2002-11-08 | 2004-06-03 | The Mclean Hospital Corporation | Compounds for the treatment of tobacco dependence and withdrawal |
BR0317586A (pt) * | 2002-12-20 | 2005-11-22 | Mclean Hospital Corp | Compostos para normalização do ciclo sono/vigìlia |
EP1727554A4 (en) * | 2003-10-08 | 2009-09-30 | Mclean Hospital Corp | METHODS OF TREATING PSYCHIATRIC DISORDERS, ALCOHOL AND DRUG ABUSE DISORDERS, AND OTHER DISORDERS USING COMBINATIONS CONTAINING OMEGA 3 FATTY ACIDS |
US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
EP1678172B1 (en) | 2003-10-15 | 2009-12-09 | Targacept, Inc. | Azabicyclic compounds for relieving pain and treating central nervous system disorders |
FR2862647B1 (fr) * | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
US20090215714A1 (en) * | 2004-06-10 | 2009-08-27 | Perry Renshaw | Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder |
WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
WO2006020703A1 (en) * | 2004-08-11 | 2006-02-23 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
US7718677B2 (en) | 2007-04-02 | 2010-05-18 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
WO2010030887A1 (en) * | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
US8853219B2 (en) | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
JP6114841B2 (ja) | 2013-02-28 | 2017-04-12 | ダーミラ, インク.Dermira, Inc. | グリコピロレート塩 |
JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 経皮薬剤送達の装置及び方法 |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
-
1992
- 1992-05-28 JP JP50062493A patent/JP3153551B2/ja not_active Expired - Fee Related
- 1992-05-28 PT PT100525A patent/PT100525B/pt active IP Right Grant
- 1992-05-28 DK DK92912971T patent/DK0588917T3/da active
- 1992-05-28 AT AT92912971T patent/ATE197454T1/de not_active IP Right Cessation
- 1992-05-28 CA CA002109585A patent/CA2109585C/en not_active Expired - Lifetime
- 1992-05-28 EP EP92912971A patent/EP0588917B1/en not_active Expired - Lifetime
- 1992-05-28 WO PCT/US1992/004631 patent/WO1992021339A1/en active IP Right Grant
- 1992-05-28 DE DE69231557T patent/DE69231557T2/de not_active Expired - Lifetime
- 1992-05-28 ES ES92912971T patent/ES2153360T3/es not_active Expired - Lifetime
- 1992-07-01 IE IE169092A patent/IE921690A1/en not_active IP Right Cessation
-
1993
- 1993-09-08 US US08/118,079 patent/US5409946A/en not_active Expired - Lifetime
-
1997
- 1997-05-14 BR BR1100981-0A patent/BR1100981A/pt active IP Right Grant
-
2001
- 2001-01-24 GR GR20010400099T patent/GR3035285T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE197454T1 (de) | 2000-11-11 |
IE921690A1 (en) | 1992-12-02 |
BR1100981A (pt) | 2000-04-18 |
ES2153360T3 (es) | 2001-03-01 |
DE69231557T2 (de) | 2001-06-21 |
PT100525B (pt) | 1999-10-29 |
EP0588917B1 (en) | 2000-11-08 |
EP0588917A1 (en) | 1994-03-30 |
PT100525A (pt) | 1993-09-30 |
JP3153551B2 (ja) | 2001-04-09 |
CA2109585C (en) | 2000-02-15 |
EP0588917A4 (pt) | 1994-04-13 |
DE69231557D1 (de) | 2000-12-14 |
CA2109585A1 (en) | 1992-12-10 |
WO1992021339A1 (en) | 1992-12-10 |
JPH06508143A (ja) | 1994-09-14 |
GR3035285T3 (en) | 2001-04-30 |
US5409946A (en) | 1995-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0588917T3 (da) | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion | |
DK0663912T3 (da) | Heterocykliske etherforbindelser til forstærkning af den kognitive funktion | |
BG102173A (en) | Aromatic compounds and pharmaceutical compositions containing them | |
BR0109703A (pt) | Derivados de piperazina | |
NO960380L (no) | Middel til behandling av neurosykdommer | |
DE69201956D1 (de) | Pyrrolidin- und thiazolidinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
HUT66971A (en) | 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof | |
ATE170530T1 (de) | Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten | |
PT649846E (pt) | Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos | |
MY132077A (en) | Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation | |
AR028802A1 (es) | El uso de ciertos compuestos de ftalazina para el tratamiento de enfermedades neovasculares oculares | |
NO973342L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer | |
CA2450274A1 (en) | Benzoxazepine derivatives and their use as ampa receptor stimulators | |
SE8503109D0 (sv) | Cyclic prodrugs of antiinflammatory oxicams | |
ATE5408T1 (de) | Cephalosporine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
AU1621392A (en) | New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them | |
ATE181331T1 (de) | Salmycine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
NO943793L (no) | Ny anvendelse av | |
EA200900312A1 (ru) | Производные 3,4-дигидробензо[1,2,3]тиадиазин-1,1-диоксида, способ их получения, лекарственные средства, содержащие указанные производные, и их применение |